Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well dabrafenib works with or without trametinib
in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether dabrafenib is more effective when given with or without trametinib in treating
thyroid cancer